Pharmacogenetics of classical and new antipsychotic drugs

Therapeutic Drug Monitoring

Volumn 22, Issue 1, 2000, Pages 118-121

  Otani, Koichi ^a   Aoshima, Toshiaki ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Antipsychotic drugs; Clinical effects; CYP2D6; Drug interactions; Pharmacogenetics

Indexed keywords

BROMPERIDOL; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; PIMOZIDE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZOTEPINE; ZUCLOPENTHIXOL;

AKATHISIA; ARTICLE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG METABOLISM; DYSTONIA; ENZYME ACTIVITY; GENOTYPE; HUMAN; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; STEADY STATE; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; GENOTYPE; HUMANS; PHARMACOGENETICS;

EID: 0033974786     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200002000-00025     Document Type: Article

References (26)

1. Bertilsson L, DabI ML. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 1996:5:200-23.
2. Llerena A, Aim C, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992:14:92-7.
3. Pan LP, Wijnant P, De Vriendt C, Rosseel T, Belpaire FM. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br J Clin Pharmacol 1997;44: 557-64.
4. Llerena A, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992;14:261-4.
5. Huang ML, Van Peer AV, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects, Clin Pharmacol Ther 1993;54: 257-68.
6. Lane HY, Hu OYP, Jann MW, Deng HC, Lin HN, Chang WH. Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatry Res 1997;69:105-11.
7. Suzuki A, Otani K, Mihara K, et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol. Pharmacogenetics 1997;7:415-8.
8. Mihara K, Suzuki A, Kondo T. et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia, Clin Pharmacol Ther 1999;65:291-4.
9. Linnet K, Wiborg O. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism, Clin Pharmacol Ther 1996;60:41-47.
10. Linnet K, Wiborg O. Influence of cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit 1996; 18:629-34.
11. Jerling M, Dahl M-L, Åberg-Wistedt A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996;59:423-428
12. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers E, Kalow W. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo, Chin Pharmacol Ther 1997;62:334-47.
13. Yasui N, Tybring G, Otani K, et al. Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmeth-ylmianserin, in depressed Japanese patients. Pharmacogenetics 1997;7:369-74.
14. Pollock BG, Mulsant BH, Sweet RA, et al. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psycho-pharmacol Bull 1995;31:327-31.
15. Meyer JW, Woggon B, Baumann P, Meyer UA. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 1990;39:613-4.
16. Spina E, Ancione M, Di Rosa AE, Meduri M, Caputi AP. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol 1992;42:347-8.
17. Arthur H, Dahl ML, Siwers B, Sjöqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 1995;15:211-6.
18. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology 1997;131:174-9.
19. Kapitany T, Meszaros K, Lenzinger E, et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998:32:101-6.
20. Ohmori O, Suzuki T, Kojima H, et al. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 1998;32:107-13.
21. Kawanishi C, Shimoda Y, Fujimaki J, et al. Mutation involving cytochrome P450 II D6 in two Japanese patients with neuroleptic malignant syndrome. J Neural Sci 1998:160:102-4.
22. Otani K, Kaneko S, Fukushima Y, Chiba K, Ishizaki T. NMS and genetic drug oxidation. Br J Psychiatry 1991:159:595-6.
23. Ueno S, Otani K, Kaneko S, et al. Cytochrome P-450 2D6 gene polymorphism is not associated with neuroleptic malignant syndrome. Biol Psychiatry 1996;40:72-4.
24. Kawanishi C, Hanihara T, Maruyama Y, et al. Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B. Psychiatr Genet 1997;7:127-9.
25. Iwahashi K, Yoshihara E, Nakamura K, et al. CYP2D6 Hha I genotype and the neuroleptic malignant syndrome. Neuropsycho-biology 1999;39:33-7.
26. Spina E, Sturiale V, Valvo S, et al. Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions. Acta Psychiatr Scand 1992;86:364-6.